This site is intended for health professionals only
Shire plc, the global specialty biopharmaceutical company, today announced that Philip J 0Vickers, PhD, has been appointed Senior Vice President of Research & Development (R&D) for its Human Genetic Therapies (HGT) business. In this position, Dr Vickers will be responsible for leading global R&D for Shire HGT and for establishing the strategic direction of the Companyâ€™s pipeline. As a member of the HGT leadership team, he will report to Sylvie GrÃ©goire, President of Shire HGT, and will play a central role in the development and execution of HGTâ€™s global business strategy.
A senior executive with more than two decades of pharmaceutical and biotechnology industry experience, Dr Vickers joins Shire from Resolvyx Pharmaceuticals where he was Chief Scientific Officer and President. While at Resolvyx, he served as a member of the Board and was accountable for all preclinical and clinical research, as well as external business development activities and collaborations. Previously, Dr Vickers was Senior Vice President and U.S. Head of Research at Boehringer-Ingelheim Pharmaceuticals, where he led a research site that focused on the therapeutic areas of cardiovascular and immunology and inflammation while managing strategic external collaborations. He also held leadership positions at Pfizer in both the US and UK, and began his career at Merck Frosst in Canada.
Dr. Vickers completed his undergraduate studies with a Bachelor of Science degree in applied biochemistry at the University of Salford, Manchester and subsequently earned a PhD in biochemistry at the University of Toronto. He was also a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland.
â€œShire HGT has grown substantially in recent years, and we are pleased to have Phil join us at a crucial time in the growth of the Company,â€ said Sylvie GrÃ©goire, President of Shire HGT. â€œHe has the breadth of experience and expertise that will enhance our scientific and business capabilities in forging the long-term vision for the Company, and we will count on him to help us deliver on our promise to patients suffering from rare genetic diseases worldwide.â€